Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care / Nazha, A., Sekeres, M.A., Komrokji, R., Steensma, D.P., Kantarjian, H., Roboz, G., Fenaux, P., Prebet, T., Azarnia, N., Zbyszewski, P.S., Fruchtman, S.M., Santini, V., Silverman, L.R., Platzbecker, U., Garcia-Manero, G.. - In: BLOOD CANCER JOURNAL. - ISSN 2044-5385. - ELETTRONICO. - 7:(2017), pp. 644-646. [10.1038/s41408-017-0018-7]
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care
Santini, Valeria;
2017
Abstract
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
| File | Dimensione | Formato | |
|---|---|---|---|
|
41408_2017_Article_18.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
523.02 kB
Formato
Adobe PDF
|
523.02 kB | Adobe PDF | Richiedi una copia all'autore |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
